- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04152187
Effects of Inspiratory Muscle Training in Patients With Pulmonary Hypertension
Investigation of the Effects of Inspiratory Muscle Training in Patients With Pulmonary Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pulmonary Hypertension (PH) is a hemodynamic finding related to increase in pulmonary artery pressure. Because PH disease is a progressive, rare disease, it is important for this disease group to prolong the life span and to increase the quality of life and functional capacity. PH patients have been shown to have weakness in peripheral and respiratory muscles.
Patients will be randomly assigned to the inspiratory muscle training and control group. Inspiratory muscle training will be initiated in accordance with the patient at a range of 40-60%. İnspiratory muscle training will be given based on the assessments by the physiotherapist. Patients with PH who come to the routine outpatient clinic and volunteer will be included in the study. The first session will be the evaluation session and the 8-week inspiratory muscle training will be given, the other group will be the control group only. Dyspnoea, diaphragm thickness, pulmonary function, respiratory and peripheral muscle strength, blood pressure, arterial stiffness, physical activity, anxiety, depression and quality of life assessments will be repeated before and after the treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Izmir, Turkey, 35320
- Dokuz Eylul University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Pulmonary Hypertension
- According to the New York Heart Association functional class II - III
- Cases receiving stable medication for 3 months
Exclusion Criteria:
- Conditions which can limit the assessments
- Severe ischemic heart disease
- Acute cor pulmonale
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control
No additional intervention
|
|
EXPERIMENTAL: Inspiratory muscle training (IMT)
Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe).
During training, patients will be instructed to maintain diaphragmatic breathing.
Inspiratory load will be set at 40-60% of maximum inspiratory pressure.
Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
|
The treatment group will receive inspiratory muscle training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 minute walk test
Time Frame: Change from Baseline at 8 weeks
|
functional capacity
|
Change from Baseline at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Physical Activity Questionnaire-Short Form
Time Frame: Change from Baseline at 8 weeks
|
The International Physical Activity Questionnaire-Short Form has 7 items listing activities and requests estimates of durations and frequencies for each activity engaged in over the past week.
Durations are multiplied by known metabolic equivalents per activity and the results for all items are summed for the overall physical activity score.
Scores for walking and for moderate and vigorous activities are sums of corresponding item scores.
Higher scores indicate higher physical activity level.
|
Change from Baseline at 8 weeks
|
Nottingham Health Profile
Time Frame: Change from Baseline at 8 weeks
|
Health-related quality of life will be assessed using Nottingham Health Profile scale which is a general quality of life questionnaire that measures perceived health problems and their impact on normal daily activities.
It has 38 items divided into six domains: energy level, pain, emotional reactions, sleep, social isolation and physical abilities.
Items use yes/no answer format and each item is weighted.
Total scores for each domain range from 0 to 100.
Higher scores represent less quality of life in relevant domain.
|
Change from Baseline at 8 weeks
|
Mouth pressures
Time Frame: Change from Baseline at 8 weeks
|
Maximal inspiratory pressure, maximal expiratory pressure and endurance will be measure with mouth pressure device
|
Change from Baseline at 8 weeks
|
Modified Medical Research Council Dyspnea Scale
Time Frame: Change from Baseline at 8 weeks
|
Modified Medical Research Council Dyspnea Scale is used to measure dyspnea.
Higher scores indicate higher dyspnea.
|
Change from Baseline at 8 weeks
|
Forced vital capacity
Time Frame: Change from Baseline at 8 weeks
|
Forced vital capacity is defined as the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
|
Change from Baseline at 8 weeks
|
Forced expiratory volume in 1 second
Time Frame: Change from Baseline at 8 weeks
|
The volume of air expired in the first second of expiration or forced expiratory volume in 1 second, especially when expressed as a ratio with the total amount of air expired during the forced vital capacity, is a good index of expiratory airways resistance.
|
Change from Baseline at 8 weeks
|
Diaphragma thickness
Time Frame: Change from Baseline at 8 weeks
|
Diaphragma thickness will be measured by two dimensional ultrasonography
|
Change from Baseline at 8 weeks
|
Levels of blood pressure
Time Frame: Change from Baseline at 8 weeks
|
Ambulatory blood pressure monitoring will be used for blood pressure measurement
|
Change from Baseline at 8 weeks
|
Arterial stiffness
Time Frame: Change from Baseline at 8 weeks
|
During blood pressure measurements, augmentation index will be measured by non-invasive oscillations over the brachial artery.
|
Change from Baseline at 8 weeks
|
Isometric muscle strength
Time Frame: Change from Baseline at 8 weeks
|
Isometric muscle strength for knee extensors and shoulder flexors and abductors
|
Change from Baseline at 8 weeks
|
Upper extremity exercise capacity
Time Frame: Change from Baseline at 8 weeks
|
Upper extremity exercise capacity will be measured with Six-Minute Pegboard and Ring Test.
In this test 4 iron rods, and a total of 20 rings are placed on a pegboard.
At the end of six minutes, total number of rings placed will count.
|
Change from Baseline at 8 weeks
|
Fatigue Impact Scale
Time Frame: Change from Baseline at 8 weeks
|
The Fatigue Impact Scale is widely used to measure fatigue.
It is a 40-item multidimensional scale measuring the physical, cognitive and social.
Patients are asked to rate how much of a problem fatigue has caused them during the past month, including the day of testing, on a 5-point Likert-type scale, with response options ranging from 0 "no problem" to 4 "extreme problem".
Loer scores indicate the better results
|
Change from Baseline at 8 weeks
|
Changes in Anxiety and Depression
Time Frame: Change from Baseline at 8 weeks
|
Anxiety and depression levels will be assessed by Hospital Anxiety and Depression Scale.
The scale consists of 14 items, seven items for the anxiety subscale and seven for the depression subscale.
Each item is scored on a response-scale with four alternatives ranging between 0 and 3. Higher scores indicate
|
Change from Baseline at 8 weeks
|
Changes in Dyspnea
Time Frame: Change from Baseline at 8 weeks
|
Dyspnea level will be questioned with the modified Borg Scale.
Minimum value is 0 (no dyspnea), and maximum value is 10 (maximal dyspnea) Higher scores indicate higher fatigue levels.
|
Change from Baseline at 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Buse Ozcan Kahraman, Dokuz Eylul University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pulmonary hypertension
- 2018.KB.SAG.099 (OTHER_GRANT: Dokuz Eylül University Scientific Research Coordination Unit)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension, Pulmonary
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on Inspiratory muscle training
-
Elisabethinen HospitalUnknownStem Cell Transplantation | Inspiratory Muscle Training | Respiratory Muscle TrainingAustria
-
Dokuz Eylul UniversityDokuz Eylül University, Scientific Research Projects Coordination UnitCompleted
-
University of British ColumbiaNatural Sciences and Engineering Research Council, CanadaCompletedRespiratory Muscles | Breathing ExercisesCanada
-
Universidad Complutense de MadridColegio Profesional de Fisioterapeutas de la Comunidad de Madrid, Madrid,...CompletedQuality of Life | Covid19 | Respiratory Muscle Training | Respiratory Function Test | Psychosocial FactorSpain
-
King Saud UniversityCompleted
-
Universidade do PortoUnknownMuscle Weakness | Dyspnea | Reactive Airways Dysfunction Syndrome (Disorder)Portugal
-
Gazi UniversityCompletedAllogeneic Hematopoietic Stem Cell Transplantation
-
Gazi UniversityCompleted
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto AlegreUnknownChronic Kidney Disease